Myelofibrosis with myeloid metaplasia (MMM) is the chronic myeloproliferative disorder associated with the poorest prognosis with a median survival of 4 years, and actually allogeneic hemopoietic stem cell transplantation (SCT) represents the only curative option. Recently, the detection of JAK2 V617F mutation in MMM, as in other Philadelphia chromosome-negative myeloproliferative diseases, has revived the prospect of targeted therapeutics as well as molecular monitoring of treatment response. This point mutation results in a substitution of valine for phenylalanine at position 617 in the JH2 domain and leads to constitutive tyrosine phosphorylation and cytokine hypersensitivity; approximately 45% of MMM cases (range 35-50%) are known to possess the JAK2 V617F mutation, although the pathogenesis of this disease still remains unclear. JAK2 V617F-positive MMM patients have been associated to a significantly higher white blood cell (WBC) count and neutrophil count than V617F-negative patients, suggesting that the mutation is associated with expansion of the myeloid lineage; positive patients also have a worse overall survival and have less requirement for transfusion than the negative cases.
Here, we describe a case of a patient with MMM in whom the JAK2 V617F mutation was shown to be eradicated after allogeneic SCT.
A The patient was found to have a human leukocyte antigenidentical brother and he was then referred for an allogeneic SCT, which was performed in May 2006. Reduced-intensity conditioning (RIC) or non-myeloablative regimen included 30 mg/m 2 fludarabine for 5 days and 140 mg/m 2 melphalan for 2 days with cyclosporine and short course of methotrexate for graft-versushost disease prophylaxis.
5 CD34 þ cells (7.9 Â 10 6 /kg) from PB were infused. Engraftment was achieved on day þ 14 posttransplantation. Post-transplantation course was unremarkable, except for cytomegalovirus and Epstein-Barr virus reactivation. Clinical improvement, according to International Working Group on MMM, 6 at current follow-up on day þ 90 posttransplantation has been documented. Bone marrow biopsy of the patient revealed grade 1 of fibrosis; spleen volume reduced to 3 cm below the costal margin and bone marrow aspirate did a b 1 2 3 4 5
Figure 1 Methods for molecular and engraftment monitoring in MMM with JAK2 V617F mutation after allogeneic SCT. (a) Allele-specific PCR for the JAK2 V617F mutation. Lane 1, patient sample before transplant; lane 2, donor; lanes 3-5, patient sample on day þ 14, þ 20 and þ 60 post-transplantation. (b) Chimerism analysis using STR method: pattern at locus D18 of recipient pre-transplantation (upper trace), donor (middle trace), recipient on day þ 14 post-transplantation (bottom trace).
Letters to the Editor not show increment of blasts; the patient also reduced his transfusion requirement (1 uRBC/every 10 days). JAK2 V617F mutation analysis, when allele-specific PCR method 7-10 became available, was retrospectively performed on genomic DNA sample obtained at diagnosis. The mutation was present in samples obtained at diagnosis and just before transplantation. The absence of the mutation was assessed on PB sample from the donor. Quantitative PCR of JAK2 V617F was not available either at diagnosis or before transplantation. JAK2 V617F mutation analysis was then reassessed on day þ 14, þ 20, þ 60 and þ 80 post-transplantation on bone marrow. No mutation was present leading to apparent JAK2 V617F eradication by allogeneic PBSCT as reported in Figure 1a . Chimerism analysis was also performed using short tandem repeat analysis at the same time intervals of JAK2 analysis, before and after SCT, showing 100% donor chimerism with no traces of DNA recipient (Figure 1b) . We could assess, thus, that JAK2 V617F mutation in this patient has apparently been eradicated by a non-myeloablative conditioning regimen followed by transplantation.
Standard-dose conditioning regimens followed by allogeneic transplantation are associated with a relatively high transplantrelated mortality in MMM. Introduction of RIC regimens has substantially reduced treatment-related mortality, expanding the access of fragile patients with MMM and achieving a 1-year survival rate of 90%.
11 Although the optimal conditioning regimen is currently unknown, our observation indicates that JAK2 V617F mutation can be eradicated shortly after RIC regimen and SCT. Molecular monitoring of treatment response in MMM is applicable to JAK2 V617F-positive cases and major molecular response could be defined as the absence of the mutation in samples of previously positive cases; however, whether eradication of mutation reflects also MMM disease resolution or a mere return to a pre-JAK2 V617F state is still unknown. L-asparaginase is a critical component of the combination chemotherapy for childhood acute lymphoblastic leukemia. It has been demonstrated to suppress the growth of leukemic cells by hydrolyzing asparagine to aspartic acid and ammonia, and causing the rapid depletion of asparagine in plasma. As a nonessential amino acid, asparagine could be synthesized from aspartate and glutamine by asparagine synthetase (AsnS) and is incorporated into amino-acid sequences of proteins. 1 Following administration of L-asparaginase, leukemic cells cannot compensate for the additional requirement of asparagine for their growth and development owing to the lack of sufficient AsnS activity.
2 The exact molecular events that cause cell death following L-asparaginase treatment keeps unknown. However, suppression of protein synthesis is an obvious potential target and it had been documented that L-asparaginase exposure could initiate apoptosis of the cells.
3 Aslanian et al. 4 overexpressed the AsnS protein in the Molt-4 cells using a Moloney mouse retrovirus system and induced the L-asparaginase resistance phenotype in the parental cells. Hutson et al. 5 demonstrated that the AsnS messsnger RNA (mRNA) level was in parallel to the AsnS protein level. Like the AsnS enzyme activity, the AsnS mRNA level was also correlated with the cellular resistance, which indicated that the AsnS mRNA level was an index of cells resistance to L-asparaginase. Therefore, our study is to investigate the possibility of reversing the L-asparaginase resistance and to further investigate the correlation of AsnS expression with Lasparaginase resistance by downregulating the AsnS mRNA level.
In a previous experiment, we had tested the AsnS mRNA and the 50% inhibiting concentration (IC 50 ) of eight cell lines
